Levodopa/Carbidopa Neuraxpharm (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor that crosses the blood‑brain barrier and is enzymatically converted to dopamine within the brain. The added carbidopa blocks peripheral conversion, ensuring more levodopa reaches the central nervous system, where dopamine deficiency underlies Parkinsonian motor signs.

The appropriate dose is individualized by the prescribing clinician based on disease severity, patient age, response to therapy, and tolerability. Dosage adjustments are made gradually to achieve optimal symptom control while minimizing side effects.

Safety data are limited; the medication should be used during pregnancy or lactation only if the potential benefits outweigh the possible risks to the fetus or infant. Clinicians must evaluate each case carefully and discuss uncertainties with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective symptomatic therapy for motor control, whereas dopamine agonists or MAO‑B inhibitors may be used earlier to delay levodopa initiation. The combination offers superior symptom relief but carries a higher risk of motor complications such as dyskinesia compared with some alternatives.

Store the tablets at ambient temperature below 25 °C, in the original packaging, and protect them from moisture and direct sunlight. Do not expose the product to excessive heat or humidity, as this may affect potency.

The medication is taken orally, usually with a glass of water. It can be taken with or without food, but high‑protein meals may interfere with absorption, so clinicians often advise spacing the dose from protein‑rich meals.

Serious adverse events include dyskinesia (involuntary movements), psychiatric disturbances such as hallucinations, severe orthostatic hypotension, and rare cardiovascular complications. Patients should be monitored regularly for these effects, especially after dose escalations.

Individuals with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in patients taking non‑selective MAO inhibitors, those with narrow‑angle glaucoma, or those with severe cardiovascular disease where rapid blood‑pressure changes could be hazardous.